Dermatology

Chronic pruritus, the hallmark symptom of atopic dermatitis (AD), is driven by a relentless itch–scratch cycle that can persist despite clinical improvements from conventional therapies.

Patients with psoriasis initiating biologic therapy, particularly tumor necrosis factor (TNF) inhibitors, may have a reduced long-term risk of developing primary malignancies compared with biologic-naïve individuals, according to a large retrospective cohort study.

Robotic-assisted techniques could one day enhance the precision of Mohs micrographic surgery (MMS) for rare cutaneous sarcomas such as dermatofibrosarcoma protuberans (DFSP), but current technology remains ill-suited for skin-level applications, according to recent research.

The clinical legitimacy of topical steroid withdrawal (TSW) remains a point of contention among dermatologists, according to new survey data from Australian specialists.

Real-world data on atopic dermatitis (AD) treatment has revealed that while current treat-to-target (T2T) strategies are feasible, several clinical targets may require refinement to better reflect meaningful outcomes.

A recent cross-sectional study sheds light on the knowledge, perceptions, and practices surrounding skin-lightening products (SLPs) among female medical students.

Therapeutic options for pediatric psoriasis are growing rapidly, with biologics and oral small molecules now playing a central role in modern treatment.

A recent systematic review of Merkel cell carcinoma (MCC) treatment in solid organ transplant (SOT) recipients reveals an urgent need for clearer treatment guidelines.